HCA Healthcare, Inc. (HCA) — BATS 1/100 — 2026-07-24

Listen to the earnings call audio for free on StockAnalysis

Summary based on HCA Healthcare, Inc. earnings call on 2026-07-24

BotFlo AI Transformation Score for $HCA: 1 (1/100)

Sector AI Transformation Score for $HCA: 0 (0/50)

Presentation

(1/5) Coverage attrition and midyear financial pressure
• ⚠️ Expiration of enhanced premium tax credits drove a larger-than-expected shift of exchange patients nearly one-for-one into uninsured status.
• 📉 Unfavorable payer mix created most of the financial pressure, with three domestic divisions accounting for about half the company impact.
• 📈 Despite headwinds, diluted EPS grew 11% in the quarter and 11% year-to-date.

(2/5) Demand strength and capacity investment
• 📈 Insured volumes excluding exchanges were solid, with ER visits, cardiac procedures, and rehab supporting improving trends.
• 🏥 Elective surgeries declined while emergency inpatient surgeries, about two-thirds of inpatient cases, were up versus last year.
• 💰 More than $7 billion of approved capital expenditures should come online over the next three years to add capacity and offerings.

(3/5) Financial resiliency program
• 🏭 Cost metrics continued to improve through the first two quarters under the financial resiliency program.
• 🤖 Management sees more resiliency capacity through digital transformation, global capabilities, and workforce development.
• 📈 HCA expects the resiliency program to add value this year and in subsequent years while preserving a culture of disciplined execution.

(4/5) Same-facility volumes, payer mix, and cost results
• 📊 Same-facility admissions rose 2.5%, equivalent admissions 2.7%, ER visits 3.6%, while inpatient and outpatient surgeries fell 2.3% and 3.4%.
• ⚠️ Exchange volumes declined 15% and the related payer-mix shift hit adjusted EBITDA by about $400 million in the quarter.
• 💰 About $400 million of incremental net Medicaid supplemental benefit was recognized, including $540 million from the Florida program, and same-facility cost per equivalent admission was essentially flat.

(5/5) Capital allocation and revised 2026 guidance
• 💵 Quarterly CapEx was $1.2 billion, share repurchases $2.1 billion, dividends $171 million, and operating cash flow $2.3 billion.
• 📉 Revised 2026 guidance includes revenue $77–$79.5 billion, adjusted EBITDA $15.4–$16.1 billion, and diluted EPS $28.70–$30.50.
• ⚠️ Guidance embeds a $1.0–$1.2 billion exchange EBITDA headwind and $300–$500 million Medicaid supplemental net benefit, with second-half Medicaid a $100–$300 million headwind.

Q&A

(1/15) Q&A: Drivers of the higher exchange headwind estimate
• 📉 Exchange volume declines of 15% matched original assumptions, but conversion to uninsured is now closer to one-for-one versus 80–85%.
• 📊 The full-year $1.0–$1.2 billion range uses first-half experience, historical attrition, and external data across scenarios.
• ⚠️ Fourth-quarter 2025 exchange growth slowed to 2.5% after reforms, creating an easier year-over-year compare later in 2026.

(2/15) Q&A: Surgery trends, electives, and HICS impact
• 🏥 Emergent inpatient surgeries are about two-thirds of inpatient cases and remain up roughly 2% year-over-year, while elective inpatient cases are down about 6%.
• ⚠️ HICS demand loss is a major but not sole driver of elective inpatient and outpatient surgery weakness amid affordability pressures.
• 📈 HCA is investing in ORs, optimizing flow, aligning physicians, and growing ASC earnings and acuity despite soft electives.

(3/15) Q&A: $7 billion capital plan and competitive positioning
• 🏥 Since 2018 HCA added beds from about 37,000 to 42,000 while occupancy rose from 71% to 75%, with another 1,000–1,200 beds in the $7 billion plan.
• 📍 Outpatient sites were up 5% year-over-year with 250–300 more facilities planned, adding roughly 10% network capacity.
• 📈 Competitive positioning is stable to growing overall, supported by strong demographic trends in key HCA states.

(4/15) Q&A: Other OpEx and resiliency outlook
• 💰 Other operating expenses are inflated by provider taxes tied to supplemental benefits, but total cash cost per adjusted admission was roughly flat to prior year.
• 🏭 Resiliency programs are expected to bend the cost curve in the second half and into 2027, with multiyear benefits from digital, global capabilities, and shared services.
• 📊 Professional fees are up about 8.5% same-facility but have moderated sequentially after prior elevated years.

(5/15) Q&A: Bridging 2Q core EBITDA to back-half guidance
• 📈 Confidence rests on continued insured volume momentum excluding exchanges after a solid second-quarter profile.
• 🏭 Strong second-quarter cost trends, resiliency execution visibility, and operating leverage support further cost improvement into 2027.
• 👥 Field and corporate management’s track record through prior challenging cycles underpins guidance confidence.

(6/15) Q&A: Divisions driving half of exchange impact
• ⚠️ Gulf Coast, North Florida, and South Atlantic divisions had heavy HICS exposure and drove much of the company impact.
• 📉 Those divisions saw composite HICS adjusted admission declines of roughly 25% to 28% in the first half.
• 📊 Two of the three divisions still have higher total volume year-over-year, but payer mix shifted sharply from HICS to uninsured.

(7/15) Q&A: Medicaid work requirements outlook for 2027
• ⚠️ Work requirements are expected to affect expansion states more than nonexpansion states because of the focus on working adults.
• 📋 HCA is monitoring the proposed rule, litigation, and state implementation while engaging states on supportive approaches.
• 👥 Parallon coverage-support teams are being strengthened to help patients through applications and work requirements, and management expects to manage impacts reasonably.

(8/15) Q&A: Surgery cadence and volume growth by payer
• 📊 Sam declined to differentiate Q2 versus year-to-date surgery explanations, preferring a midyear view over 90-day judgments.
• 📈 Q2 same-facility equivalent admissions: Medicare +3.6%, Medicaid +2.7%, commercial ex-exchanges +2.4%, exchanges -15%, uninsured +15%.
• ⚠️ Combining HICS and uninsured keeps inpatient payer-mix shares stable year-over-year, reinforcing the one-for-one migration narrative on roughly 22,000 exchange losses.

(9/15) Q&A: Multi-year exchange attrition planning
• 📉 Management still expects 2027 exchange coverage losses to be less than 2026 even with emerging premium increases.
• 📋 The estimate assumes core ACA premium tax credits continue without new enhanced support.
• ⚠️ Most 2026 attrition is attributed to loss of enhanced credits, after which 2027 is expected to return toward a more normal course.

(10/15) Q&A: Florida DPP recognition and visibility
• 💰 Second quarter included $400 million incremental net supplemental benefit, of which $540 million related to Florida for October 2024 through June 2026.
• 📊 Prior-year second-quarter retro payments partially offset the Florida benefit in the net figure.
• ✅ Comfort with accruing SFY2026 reflects the long-standing program, state preapproval submission, July cash receipts, and guidance that also accrues Q4 2026.

(11/15) Q&A: Monthly surgery cadence and proposed OPPS rule
• 🚫 Management does not comment on mid-quarter monthly volume progression.
• 📈 HCA is generally pleased with proposed inpatient and outpatient payment updates in aggregate, especially outpatient.
• ⚠️ Month-to-month comparisons are skewed by business-day alignment, so longer runs are preferred to judge demand.

(12/15) Q&A: IDR hyperscaling and No Surprises Act dynamics
• 🏥 HCA is almost universally in-network across facilities and participates in roughly 80–85% of available exchange payer contracts.
• 📋 After Valesco, hospital-based services are largely integrated into contracts, so very few accounts go through IDR.
• ⚠️ Sam lacks a full industry view on IDR cost impact but hopes contracts reduce need for the process as the framework matures.

(13/15) Q&A: Professional fees for anesthesia and radiology
• 📊 Same-facility professional fees grew about 8.5% in the quarter and almost 10% year-to-date, showing some stability after prior spikes.
• 🏥 Valesco helped stabilize emergency and hospital-medicine physician costs, while anesthesia and radiology remain the elevated components.
• 🏭 Teams are applying a people-process-technology playbook to anesthesia and radiology and feel better positioned than in recent years.

(14/15) Q&A: Uninsured build and Texas Medicaid conversions
• 📊 About 80% of uninsured volume growth is the one-for-one exchange migration and about 20% is slower Medicaid conversions.
• ⚠️ Emergency Medicaid applications, mostly from undocumented patients, are down, reducing conversions.
• 📍 Fewer self-pay patients are qualifying for Medicaid, with Texas uniquely affected among HCA markets.

(15/15) Q&A: Building blocks behind the EBITDA guidance cut
• 📉 After exchange and supplemental-payment assumption changes, roughly $500 million of guidance reduction reflects moderated core growth versus 2025 and initial 2026 plans.
• 📈 On an adjusted basis the update implies a return toward long-term adjusted EBITDA growth, possibly near the top of the 4–6% range.
• ✅ Original guidance started a bit above the long-term growth algorithm; first-half experience brought the outlook back to that algorithm.